Abstract: Pharmaceutically-active BHT-omega pyridyl ethers of the formula selected from BHT-omega-pyridyl ether compounds of the formula: ##STR1## wherein m=1,3for m=1, .SIGMA.=6-9for m=3, .SIGMA.=5-11Sum (.SIGMA.)=[m+n+1 (for oxygen)]wherein the bond between the two carbon atoms of the (CH.sub.2).sub.n moiety most closely adjacent the pyridine ring is a single, double, or triple bond, and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and a method of combating lipidemia and atherosclerosis therewith, are disclosed.

Abstract: N-oxides of pyridyl carboxylic acid esters of the following formula are described: ##STR1## wherein R is ##STR2## wherein X is a hydrogen atom, straight or branched C.sub.1 -C.sub.5 -alkyl, C.sub.5 -C.sub.12 -cycloalkyl, 1-adamantyl, or cyclohexylacetyl, andwherein Y is a hydrogen atom, straight or branched C.sub.1 -C.sub.5 -alkyl, 2-ethylbenzofuranoyl-3, C.sub.5 -C.sub.12 -cycloalkyl, or 2-[(4-chlorophenoxy)-2-methylpropanoyloxy]ethyl;a process for the manufacture thereof, pharmaceutical compositions containing these compounds, and method of using the same. These compounds are suited for use in the treatment of hyperlipidemas.

Abstract: Novel hypolipidemic nicotinates and related esters, being phenoxy organic compounds, are disclosed, as well as pharmaceutical compositions thereof and method of treating hyperlipidemia therewith.

Abstract: Novel N-(trimethoxybenzyl)-piperazines of the formula: ##STR1## wherein R is trifluoromethyl, hydroxy, nitro, halogen, lower-alkyl, or lower-alkoxy;R' is hydrogen, trifluoromethyl, halogen, lower-alkyl, or lower-alkoxy;R" is hydrogen or lower-alkoxy,or wherein R and either R' or R" together stand for lower-alkylene dioxy, and acid addition salts thereof, a method of preparing same, pharmaceutical compositions thereof, and a method of enhancing circulation, especially cerebrovascular circulation, therewith, are disclosed.

Abstract: Novel N-(trimethoxybenzyl)-piperazines of the formula: ##STR1## wherein A= ##STR2## wherein R is trifluoromethyl, hydroxy, nitro, halogen, lower-alkyl, or lower-alkoxy;R' is hydrogen, trifluoromethyl, halogen, lower-alkyl, or lower-alkoxy;R" is hydrogen or lower-alkoxy,or wherein R and either R' or R" together stand for lower-alkylene dioxy, and acid addition salts thereof, a method of preparing same, pharmaceutical compositions thereof, and a method of enhancing circulation, especially cerebrovascular circulation, therewith, are disclosed.

Abstract: Novel hypolipidemic nicotinates and related esters, being phenoxy organic compounds, are disclosed, as well as pharmaceutical compositions thereof and method of treating hyperlipidemia therewith.

Abstract: Certain 1,3,5-trisubstituted adamantane compounds having central nervous system activity, especially anti-Parkinsonism activity, method of preparing same, and pharmaceutical compositions thereof, method of influencing the central nervous system therewith.

Abstract: The application discloses a novel improved process for the production of .alpha.-[2-(p-chlorophenoxy)-isobutyl]-.beta.-nicotinoyl glycol ester, a known compound having a lipid-lowering effect, by the reaction of .alpha.-[2-chlorophenoxy)-isobutyryl]-.beta.-ethyl chloride ester with an alkali salt of nicotinic acid, preferably sodium nicotinate, preferably in a high-boiling polar or dipolar aprotic solvent, especially dimethylformamide, most preferably at a temperature of about 120.degree. - 180.degree. C., and most advantageously in refluxing dimethylformamide. An unpredictable increase in yields of the desired product over yields attainable by previously-available processes is thereby obtained.

Abstract: Novel hypolipidemic nicotinates and related esters, being phenoxy organic compounds, are disclosed, as well as pharmaceutical compositions thereof and method of treating hyperlipidemia therewith.